The diagnosis of young-onset dementia.

Dementia Research Centre, Department of Neurodegeneration, UCL Institute of Neurology, Queen Square, London, UK.
The Lancet Neurology (Impact Factor: 21.82). 08/2010; 9(8):793-806. DOI: 10.1016/S1474-4422(10)70159-9
Source: PubMed

ABSTRACT A diagnosis of dementia is devastating at any age but diagnosis in younger patients presents a particular challenge. The differential diagnosis is broad as late presentation of metabolic disease is common and the burden of inherited dementia is higher in these patients than in patients with late-onset dementia. The presentation of the common degenerative diseases of late life, such as Alzheimer's disease, can be different when presenting in the fifth or sixth decade. Moreover, many of the young-onset dementias are treatable. The identification of causative genes for many of the inherited degenerative dementias has led to an understanding of the molecular pathology, which is also applicable to later-onset sporadic disease. This understanding offers the potential for future treatments to be tailored to a specific diagnosis of both young-onset and late-onset dementia.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Goal. To clarify the development, the retention and the decline of cognitive abilities and to assess the differences of trend between verbal and visuospatial performance in normal aging. Method. In this study participated 90 subjects: 30 younger subjects (age 18-30), 30 adult subjects (age 40 - 55), 30 elderly subjects (age 65-80). All subjects were tested with neuropsychological verbal and visuo-spatial type test. Findings. The statistical analysis of data showed that group of adult have better performance compared to the young and the elderly subjects, both in the verbal tasks and in the visuo-spatial performance. The young group have better spatial than verbal performances. Conclusions. The cognitive abilities change during the age. In young the spatial competences are better then verbal, on other wise, in adult the verbal competence are better then spatial ones. This pattern is preserved in the group of senior.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is generally accepted that the population rate of early onset Alzheimer's disease (EOAD) in Alzheimer's disease (AD) is 1-2%. However, the true population based rate of EOAD has never been verified by a systematic review and meta-analysis. We used electronic searches of Cochrane Library, Embase, Medline and PubMed databases to identify published related studies. The systematic review and meta-analysis was then to be conducted to calculate a pooled rate of EOAD and make comparisons between studies and geographic distribution. A total of 13 papers were included in our systematic review and meta-analysis. The rate of EOAD, 5.5% [95% confidence interval (CI): 0.039-0.079, P<0.001], was generated after pooled analysis of all studies in random effect model. The pooled analysis of the rate in developed country was 5.9% (95% CI: 0.040-0.085, P<0.001). The pooled analysis of the rate in developing countries was 4.4% (95% CI: 0.028-0.066, P<0.001). Our study showed that the rate of EOAD in AD is 5.5%, not 1-2% as usually demonstrated. And our results indicated that the rate in developed countries was relative higher than in developing countries. Further trials with larger samples across more countries and more careful designed of experiments are required to confirm whether our findings are truly significant.
    03/2015; 3(3):38. DOI:10.3978/j.issn.2305-5839.2015.01.19
  • [Show abstract] [Hide abstract]
    ABSTRACT: OSA is associated with significant adverse outcomes with far-reaching health-care implications. OSA is much more common and severe in patients with Down syndrome (DS) than in the general population, yet there is a striking lack of literature in this area. In this review article, we have summarized the current state of knowledge and presented the available data on OSA in DS. The higher prevalence and severity of OSA in patients with DS may be related to unique upper airway anatomic features as well as increased risk for obesity, hypothyroidism, gastroesophageal reflux disease, and generalized hypotonia. Although many of the manifestations of OSA in patients with DS are similar to those seen in the general population, the relative morbidity is significantly higher. For individuals with DS who already face cognitive challenges, the added impact of OSA on cognitive function may hinder their ability to function independently and reach their full potential. Screening and evaluation for OSA should be done in children and adults with DS. Treatment of OSA in DS involves the use of CPAP, upper airway surgery, and dental appliances, along with weight-reduction strategies, nasal steroids, and oral leukotriene modifiers as adjunctive treatments. The treatment plan should be individualized for each patient with DS, taking into account age, comorbid conditions, and barriers to treatment adherence. Future research should aim to better characterize OSA, further evaluate neurocognitive outcomes, and evaluate the efficacy of treatments in patients with DS.
    Chest 02/2015; 147(2):570-9. DOI:10.1378/chest.14-0266 · 7.13 Impact Factor

Full-text (2 Sources)

Available from
Dec 12, 2014